Determinazione degli anticoagulanti orali diretti in regime di urgenza

Pradaxa (dabigatran). Highlights of prescribing information. Boehringer Ingelheim Pharmaceuticals. Inc. 2015. Last update January 2015. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (Accesso 30 novembre 2017)

Xarelto (rivaroxaban). Highlights of prescribing information. 2015. Last update January 2015. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf (Accesso 30 novembre 2017)

Eliquis (apixaban). Highlights of prescribing information. Bristol-Myers Squibb. 2014. Last update August 2014. http://packageinserts.bms.com/pi/pi_eliquis.pdf (Accesso 30 novembre 2017)

Tripodi A (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035

Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49:761–772

Hawes EM, Deal AM, Funk-Adcock D et al. (2013) Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 11:1493–1502

Hapgood G, Butler J, Malan E et al. (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315

Barrett YC, Wang Z, Knabb RM (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 19:522–528

Douxfils J, Chatelain C, Chatelain B et al. (2013) Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 110:283–294

Cuker A, Siegal DM, Crowther MA et al. (2014) Laboratory measurement of the anticoagulant activity of the non vitamin K oral anticoagulants. J Am Coll Cardiol 64:1128–1139

Schmitz EM, Boonen K, van den Heuvel DJ et al. (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12:1636–1646

Avecilla ST, Ferrell C, Chandler WL et al. (2012) Plasma-Diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 137:572–574

Baglin T (2013) The role of laboratory in treatment with new oral anticoagulants. J. Thromb Haemost 11(Suppl 1):122–128

Baglin T, Hillarp A, Tripodi A et al. (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost 11:756–760. doi: 10.1111/jth.12149

Asmis LM, Alberio L, Angelillo-Scherrer A et al. (2012) Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb Res 129:492–498

Lippi G, Di Iorio G, Testa S et al. (2013) Documento di consenso FCSA, SIMeL, SIBioC e CISMEL sul monitoraggio di laboratorio dei nuovi farmaci anticoagulanti orali. Riv Ital Med Lab 9:131–133